2731-9377

BJC Reports

Springer Science and Business Media LLC

View prefix report (10.1038)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 138 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact138 DOIs
2

Add abstracts to 101 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact101 DOIs
3

Deposit reference lists for 7 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact7 DOIs

DOIs for this ISSN

Showing the top 5 of 230 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Efficacy and safety of sacituzumab govitecan Trop-2-targeted… (10.1038/s44276-024-00106-1)
Abstract ORCID
68.09 22
2 Hereditary gastrointestinal polyposis syndromes Rare Disease… (10.1038/s44276-023-00011-z)
Abstract References ORCID
52.42 4
3 Overall survival after CDK4/6 inhibitor dose reduction in wo… (10.1038/s44276-024-00108-z)
Abstract ORCID
50.00 9
4 New light on chemotherapy toxicity and its prevention (10.1038/s44276-024-00064-8)
ORCID
48.11 83
5 Targeting PLOD2 suppresses invasion and metastatic potential… (10.1038/s44276-024-00085-3)
Abstract ORCID
47.71 8
6 The impact of elective cervical lymph node treatment on the… (10.1038/s44276-024-00095-1)
Abstract ORCID
47.71 8
7 Towards replicability and sustainability in cancer research (10.1038/s44276-024-00090-6)
Abstract ORCID
45.15 7
8 Ropeginterferon alfa-2b shows anti-polycythaemia vera activi… (10.1038/s44276-024-00076-4)
Abstract ORCID
42.25 6
9 Therapeutic vulnerabilities and pan-cancer landscape of BRAF… (10.1038/s44276-024-00086-2)
Abstract ORCID
42.25 6
10 Small extracellular vesicles as biomarkers of response in re… (10.1038/s44276-024-00096-0)
Abstract ORCID
42.25 6
11 A novel multigene panel (Sig27) robustly predicts poor progn… (10.1038/s44276-025-00128-3)
Abstract ORCID
42.25 6
12 Solid lipid nanoparticles in pancreatic cancer treatment (10.1038/s44276-025-00130-9)
Abstract ORCID
42.25 6
13 Evaluating the significance of combining PD-L1 and TILs as b… (10.1038/s44276-025-00174-x)
Abstract ORCID
42.25 6
14 A detoxified TLR4 agonist inhibits tumour growth and lung me… (10.1038/s44276-024-00120-3)
Abstract ORCID
38.91 5
15 Circulating tumour DNA assays in focus: highlights from ASCO… (10.1038/s44276-025-00181-y)
Abstract ORCID
38.91 5
16 Artificial intelligence-powered discovery of small molecules… (10.1038/s44276-023-00035-5)
ORCID
37.28 30
17 Viruses in glioblastoma: an update on evidence and clinical… (10.1038/s44276-024-00051-z)
ORCID
37.28 30
18 Breaking barriers: we need a multidisciplinary approach to t… (10.1038/s44276-025-00129-2)
ORCID
36.56 28
19 Commentary: Why is genetic testing underutilized worldwide?… (10.1038/s44276-024-00099-x)
Abstract
34.95 24
20 Circulating tumor DNA monitoring detects minimal residual di… (10.1038/s44276-025-00158-x)
Abstract ORCID
34.95 4
21 Long-term outcomes of consecutive patients of oropharyngeal… (10.1038/s44276-025-00164-z)
Abstract ORCID
34.95 4
22 B cells and tertiary lymphoid structures in cancer therapy r… (10.1038/s44276-025-00146-1)
Abstract
34.04 22
23 Exploring the prognostic impact of absolute lymphocyte count… (10.1038/s44276-024-00058-6)
ORCID
33.56 21
24 Increasing use of artificial intelligence in genomic medicin… (10.1038/s44276-025-00135-4)
Abstract
31.97 18
25 Impact of underlying liver disease on unresectable hepatocel… (10.1038/s44276-024-00038-w)
ORCID
31.38 17
26 What’s in a name? Refining the nomenclature of liver metasta… (10.1038/s44276-023-00018-6)
Abstract ORCID
30.10 3
27 Survival benefit of cytoreductive surgery in patients with p… (10.1038/s44276-024-00084-4)
Abstract ORCID
30.10 3
28 CNS prophylaxis is (mostly) futile in DLBCL (10.1038/s44276-024-00087-1)
Abstract ORCID
30.10 3
29 Long-term survival following anti-PD-(L)1 monotherapy in adv… (10.1038/s44276-024-00104-3)
Abstract ORCID
30.10 3
30 Metabolic reprogramming in glioblastoma: a rare case of recu… (10.1038/s44276-025-00134-5)
Abstract ORCID
30.10 3
31 Monitoring circulating tumor DNA by recurrent hotspot mutati… (10.1038/s44276-025-00143-4)
Abstract ORCID
30.10 3
32 Treatment with checkpoint inhibitors for unresectable non-me… (10.1038/s44276-025-00171-0)
Abstract ORCID
30.10 3
33 Metformin may improve the outcome of patients with colorecta… (10.1038/s44276-023-00022-w)
ORCID
29.40 14
34 HER2 amplification and HER2 low expression in endometrial ca… (10.1038/s44276-025-00125-6)
Abstract
29.40 14
35 Genomic profiling and clinical utility of circulating tumor… (10.1038/s44276-024-00049-7)
ORCID
28.65 13
36 Climate change: why oncologists need to get involved (10.1038/s44276-023-00023-9)
ORCID
27.85 12
37 Cancer risk according to lifestyle risk score trajectories:… (10.1038/s44276-025-00141-6)
Abstract
26.98 11
38 Gut microbiome and nutrition-related predictors of response… (10.1038/s44276-023-00008-8)
ORCID
26.03 10
39 A Phase 2 study of nivolumab in combination with modified FO… (10.1038/s44276-023-00028-4)
ORCID
26.03 10
40 Single cell atlas of kidney cancer endothelial cells reveals… (10.1038/s44276-024-00047-9)
ORCID
26.03 10
41 Determining the efficacy of ExThera Seraph100 blood filtrati… (10.1038/s44276-024-00069-3)
ORCID
26.03 10
42 Predictive biomarkers for the efficacy of PARP inhibitors in… (10.1038/s44276-025-00122-9)
ORCID
26.03 10
43 The natural history of neurolymphomatosis (10.1038/s44276-024-00053-x)
ORCID
25.00 9
44 Tumour reoxygenation after intratumoural hydrogen peroxide (… (10.1038/s44276-024-00098-y)
ORCID
25.00 9
45 Increased potentiation of 5-fluorouracil induced thymidylate… (10.1038/s44276-024-00111-4)
ORCID
25.00 9
46 Deep-learning enabled combined measurement of tumour cell de… (10.1038/s44276-025-00123-8)
ORCID
25.00 9
47 Next-generation sequencing outperforms Proactive Molecular R… (10.1038/s44276-025-00145-2)
Abstract
25.00 9
48 Prevalence of the human papillomavirus (HPV) types among cer… (10.1038/s44276-023-00012-y)
ORCID
23.86 8
49 Integrity matters in oncology: AORTIC takes a stand against… (10.1038/s44276-023-00032-8)
Abstract ORCID
23.86 2
50 Breast cancer risk assessment based on susceptibility genes… (10.1038/s44276-024-00100-7)
Abstract ORCID
23.86 2